Intensity Therapeutics, Inc. Common stock (INTS) News Today → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Free INTS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIntensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024finance.yahoo.com - April 2 at 12:39 PMOutlook Therapeutics Inc.wsj.com - March 18 at 9:12 AMIntensity Therapeutics Inc.: Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - March 15 at 10:49 AMIntensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - March 14 at 5:45 PMIntensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024prnewswire.com - March 14 at 8:00 AMIntensity Therapeutics to Present at the 2024 BIO CEO & Investor Conferencefinance.yahoo.com - February 21 at 8:29 AMIntensity Therapeutics to Present at the 2024 BIO CEO & Investor Conferenceprnewswire.com - February 21 at 8:01 AMIntensity Therapeutics Unveils New Incentive Compensation Planmsn.com - February 8 at 10:53 AMPerspective Therapeutics prices stock offering of $60.0M and $20.8M private placementmsn.com - January 18 at 9:04 AMINTS Intensity Therapeutics, Inc.seekingalpha.com - January 11 at 9:14 AMIntensity Therapeutics Inc.: Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Programfinanznachrichten.de - January 3 at 11:20 AMIntensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Programfinance.yahoo.com - January 3 at 11:20 AMIntensity Therapeutics (NASDAQ:INTS) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - December 29 at 7:31 AMIntensity Therapeutics Inc INTSmorningstar.com - December 27 at 8:42 PMCheckpoint stock plunges 50% on FDA rejection of skin cancer drugmsn.com - December 18 at 2:06 PMmarketbeat.com - December 15 at 3:54 PMIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officerfinance.yahoo.com - December 12 at 9:43 AMIntensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Updatefinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcomafinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023finance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Updatefinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposiumfinance.yahoo.com - December 11 at 8:16 AMIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCSfinance.yahoo.com - December 11 at 8:16 AMmarketbeat.com - December 8 at 2:27 PMmarketbeat.com - December 8 at 11:24 AMmarketbeat.com - December 5 at 9:35 AMmarketbeat.com - December 4 at 11:15 AMmarketbeat.com - December 4 at 10:51 AMmarketbeat.com - December 4 at 10:22 AMmarketbeat.com - December 4 at 9:44 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2022 Earnings Call Transcriptinsidermonkey.com - March 11 at 7:24 AMTravere Therapeutics Stock (NASDAQ:TVTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - March 3 at 10:02 PMIntensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancersfinance.yahoo.com - February 14 at 4:42 PMIntensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancersfinance.yahoo.com - February 14 at 4:42 PMIntensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022finance.yahoo.com - February 14 at 4:42 PMIntensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)finance.yahoo.com - February 14 at 4:42 PM Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Email Address 4 coins to be the “Next Bitcoin” (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 INTS Media Mentions By Week INTS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INTS News Sentiment▼1.890.33▲Average Medical News Sentiment INTS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INTS Articles This Week▼11▲INTS Articles Average Week Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AVRO News Today LENZ News Today ALGS News Today QNCX News Today ENTX News Today CDTX News Today IKNA News Today GNTA News Today DYAI News Today NKGN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INTS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyWall Street Legend Issues New NVDA WarningChaikin AnalyticsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
